Neoadjuvante Radiochemotherapie oder Chemotherapie beim lokal fortgeschrittenen Ösophaguskarzinom?

Babic, Benjamin; Fuchs, Hannah; Bruns, Christiane

doi:10.1007/s00104-020-01150-6

Cited by 18 publications

(7 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although new chemotherapeutic drugs and chemotherapy protocols have been rapidly updated in recent years, 5-fluorouracil (5-FU)-based chemotherapy protocols still have critical effect on treating EC 19 , 20 . Nonetheless, chemotherapy resistance is still the biggest factor limiting the clinical application of 5-FU in EC, and its molecular mechanism is complex and changeable 21 .…”

Section: Introductionmentioning

confidence: 99%

Long noncoding RNA SNHG6 silencing sensitized esophageal cancer cells to 5-FU via EZH2/STAT pathway

Tan

Liu

Wang

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Chemotherapy was the main treatment method for esophageal cancer (EC) patients. However, chemotherapy resistance due to multiple factors is a major barrier to EC treatment. For investigating how small nucleolar RNA host gene 6 (SNHG6) affected the 5-fluorouracil (5-FU) resistance in EC as well as its possible molecular mechanism. This work conducted cell viability assay, clone formation, scratch assays together with cell apoptosis for evaluating the roles of SNHG6 and enhancer of zeste homolog 2 (EZH2, the histone-lysine N-methyltransferase). Relevant molecular mechanism was identified by RT-qPCR analysis together with Western-blot (WB) assays. Our data showed that SNHG6 expression increased in EC cells. SNHG6 promotes colony formation and migration, whereas suppresses EC cell apoptosis. SNHG6 silencing markedly promoted 5-FU-mediated suppression on KYSE150 and KYSE450 cells. Additional mechanism studies showed that SNHG6 modulating STAT3 and H3K27me3 via promoting EZH2 level. Similar to the function of SNHG6, abnormal expression of EZH2 promotes the malignancy of EC and intensifies its resistance to 5-FU. In addition, overexpression of EZH2 abolished the role of SNHG6 silencing in 5-FU sensitivity in EC cells. SNHG6 overexpression promoted malignancy of EC and increased EC cell resistance to 5-FU. Besides, further molecular mechanism studies provided a novel regulatory pathways that SNHG6 knockdown promoted EC cell sensitivity to 5-FU by modulating STAT3 and H3K27me3 via promoting EZH2 expression.

show abstract

Section: Introductionmentioning

confidence: 99%

Long noncoding RNA SNHG6 silencing sensitized esophageal cancer cells to 5-FU via EZH2/STAT pathway

Tan

Liu

Wang

et al. 2023

Sci Rep

View full text Add to dashboard Cite

show abstract

“… 3 This strategy enables tumor down‐staging before surgery, allowing for improved prognosis. 3 , 4 The use of chemoradiation alone with curative intent remains controversial. 5 According to European Society for Medical Oncology clinical guidelines, definitive ChRT might be considered for locally advanced ESCC patients, 6 whereas for EAC, either perioperative chemotherapy or neoadjuvant ChRT should be considered standard of care, followed by esophagectomy in patients with locally advanced disease.…”

Section: Introductionmentioning

confidence: 99%

“…Currently, neoadjuvant chemoradiation therapy (ChRT) followed by esophagectomy is standard of care for ECa patients with locally advanced disease (cT3‐T4) of both histological subtypes 3 . This strategy enables tumor down‐staging before surgery, allowing for improved prognosis 3,4 . The use of chemoradiation alone with curative intent remains controversial 5 .…”

Section: Introductionmentioning

confidence: 99%

DNA methylation biomarkers accurately detect esophageal cancer prior and post neoadjuvant chemoradiation

et al. 2023

View full text Add to dashboard Cite

Background Esophageal cancer (ECa) is associated with high mortality, mostly due to late diagnosis, precluding curativeintent surgery. Hence, neoadjuvant chemoradiation (ChRT) is recommended in most patients regardless of histological subtype. A proportion of these patients, however, achieve complete disease remission and might be spared of radical surgery. The lack of reliable, minimally invasive biomarkers able to detect post‐ChRT disease persistence is, nonetheless, a major drawback. We have previously shown that miRNA promotor methylation enables accurate cancer detection in tissues and liquid biopsies but has been seldom explored in ECa patients. Aims Herein, we sought to unveil and validate novel candidate biomarkers able to detect ECa prior and post ChRT. Materials and Methods Promoter methylation of miR129‐2, miR124‐3 and ZNF569 was assessed, using quantitative methylation‐specific PCR (qMSP), in tissue samples from normal esophagus, treatment‐naïve and post‐ChRT ECa, as well as in liquid biopsies from ECa patients. Results All genes disclosed significantly different promoter methylation levels between ECa and normal esophagus, accurately detecting post‐ChRT disease, especially for adenocarcinoma. Remarkably, miR129‐2me/ZNF569me methylation panel identified ECa in liquid samples with 53% sensitivity and 87% specificity. Discussion MiR129‐2me, miR124‐3me and ZNF569me accurately discriminate ECa, either pre‐ or post‐ChRT, from normal tissue, enabling ECa detection. Furthermore, circulalting methylation‐based biomarkers are promising minimally invasive tools to detect post‐ChRT residual ECa. Conclusion Overall, our results encourage the use of miRNA methylation biomarkers as accurate ECa detection tools as a novel approach for ChRT response monitoring.

show abstract

“…e surgery treatment hurts vitality, and the use of radiotherapy and chemotherapy is clinically controversial. In this regard, the National Comprehensive Cancer Network (NCCN) [5] guidelines identified NCRT as the preoperative radiotherapy and chemotherapy of patients to facilitate the surgery through tumor downgrading and tumor retraction [6].…”

Section: Introductionmentioning

confidence: 99%

Low-Rank Matrix Denoising Algorithm-Based MRI Image Feature for Therapeutic Effect Evaluation of NCRT on Rectal Cancer

2021

Journal of Healthcare Engineering

View full text Add to dashboard Cite

This study aimed to explore the therapeutic effects of neoadjuvant chemoradiotherapy (NCRT) on rectal cancer patients using the MRI based on low-rank matrix denoising algorithm, which was then compared with the postoperative pathological examination to evaluate its application value in tumor staging after NCRT treatment. 15 patients with rectal cancer who met the requirements of radiotherapy and chemotherapy after conventional MRI were selected as the research subjects. The conventional MRI images before and after NCRT treatment were divided in two groups. One group was not processed and set as the conventional group; the other group was processed with low-rank matrix denoising algorithm and set as the optimized group. The two groups of images were observed for the changes in the ADC value and length and thickness of the tumor before and after NCRT treatment. The two groups were compared with the pathological examination for the complete remission of pathology (pCR) after the NCRT treatment and the tumor stage results. The results showed that Root Mean Square Error (RMSE) and Peak Signal to Noise Ratio (PSNR) (18.9121 and 74.9911 dB) after introducing the low-rank matrix denoising algorithm were significantly better than those before (20.1234 and 70.1234 dB) ( P < 0.05 ); there were notable differences in the tumor index data within the two groups before and after NCRT treatment ( P < 0.05 ), indicating that the NCRT treatment was effective. The pathological examination results of pCR data of the two groups were not much different ( P > 0.05 ); the examination results between the two groups were different, but no notable difference was noted ( P < 0.05 ); in the optimized group, there was no notable difference between the MRI results and the pathological examination results ( P < 0.05 ), while in the conventional group, there were notable differences in the MRI results and pathological examination results ( P < 0.05 ). In conclusion, MRI images based on low-rank matrix denoising algorithm are clearer, which can improve the diagnosis rate of patients and better display the changes of the microenvironment after NCRT treatment. It also indicates that NCRT treatment has significant clinical effects in the treatment of rectal cancer patients, which is worth promoting.

show abstract

Neoadjuvante Radiochemotherapie oder Chemotherapie beim lokal fortgeschrittenen Ösophaguskarzinom?

Cited by 18 publications

References 27 publications

Long noncoding RNA SNHG6 silencing sensitized esophageal cancer cells to 5-FU via EZH2/STAT pathway

Long noncoding RNA SNHG6 silencing sensitized esophageal cancer cells to 5-FU via EZH2/STAT pathway

DNA methylation biomarkers accurately detect esophageal cancer prior and post neoadjuvant chemoradiation

Low-Rank Matrix Denoising Algorithm-Based MRI Image Feature for Therapeutic Effect Evaluation of NCRT on Rectal Cancer

Contact Info

Product

Resources

About